UBS Group
PRQR icon

UBS Group’s ProQR Therapeutics PRQR Stock Holding History

UBS Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$495K Sell
305,264
-492,400
-62% -$807K ﹤0.01% 6095
2025
Q4 		$1.61M Buy
797,664
+703,114
+744% +$1.64M ﹤0.01% 5161
2025
Q3 		$201K Sell
94,550
-1,049,285
-92% -$2.29M ﹤0.01% 6665
2025
Q2 		$2.33M Sell
1,143,835
-643,214
-36% -$1.05M ﹤0.01% 4652
2025
Q1 		$2.38M Sell
1,787,049
-523,001
-23% -$1.11M ﹤0.01% 4562
2024
Q4 		$6.12M Buy
2,310,050
+2,307,150
+79,557% +$7.33M ﹤0.01% 3595
2024
Q3 		$5.28K Sell
2,900
-24,646
-89% -$46.3K ﹤0.01% 8072
2024
Q2 		$45.7K Buy
27,546
+22,576
+454% +$43.8K ﹤0.01% 6760
2024
Q1 		$11.4K Buy
4,970
+1,070
+27% +$2.29K ﹤0.01% 7183
2023
Q4 		$7.72K Sell
3,900
-6,144
-61% -$9.44K ﹤0.01% 7608
2023
Q3 		$13.1K Buy
10,044
+5,363
+115% +$8.44K ﹤0.01% 7001
2023
Q2 		$7.58K Buy
4,681
+1,081
+30% +$2.11K ﹤0.01% 7279
2023
Q1 		$7.67K Buy
3,600
+656
+22% +$2.01K ﹤0.01% 7786
2022
Q4 		$10.9K Sell
2,944
-2,154
-42% -$2.82K ﹤0.01% 8461
2022
Q3 		$4K Buy
+5,098
New +$4.09K ﹤0.01% 9380
2022
Q1 		– Sell
-84,327
Closed -$675K – 10757
2021
Q4 		$675K Sell
84,327
-9,789
-10% -$74.5K ﹤0.01% 4732
2021
Q3 		$787K Buy
94,116
+32,103
+52% +$210K ﹤0.01% 4385
2021
Q2 		$418K Sell
62,013
-28,602
-32% -$184K ﹤0.01% 4867
2021
Q1 		$599K Sell
90,615
-381,488
-81% -$1.95M ﹤0.01% 4733
2020
Q4 		$1.98M Sell
472,103
-6,222
-1% -$26.3K ﹤0.01% 3419
2020
Q3 		$2.29M Sell
478,325
-3,941
-0.8% -$20.6K ﹤0.01% 2928
2020
Q2 		$2.93M Sell
482,266
-343
-0.1% -$1.85K ﹤0.01% 2517
2020
Q1 		$2.65M Sell
482,609
-25,277
-5% -$194K ﹤0.01% 2494
2019
Q4 		$5.03M Buy
507,886
+56,193
+12% +$438K ﹤0.01% 2595
2019
Q3 		$2.6M Sell
451,693
-15,092
-3% -$121K ﹤0.01% 3049
2019
Q2 		$4.25M Buy
+466,785
New +$5.51M ﹤0.01% 2462
2019
Q1 		– Sell
-2,854,433
Closed -$45M – 8061
2018
Q4 		$45M Buy
2,854,433
+2,854,207
+1,262,923% +$52.4M 0.02% 636
2018
Q3 		$4K Buy
+226
New +$2.4K ﹤0.01% 7580
2018
Q2 		– Sell
-2,897
Closed -$9K – 8183
2018
Q1 		$9K Buy
2,897
+1,003
+53% +$3.23K ﹤0.01% 6945
2017
Q4 		$6K Sell
1,894
-518
-21% -$1.86K ﹤0.01% 7311
2017
Q3 		$12K Buy
2,412
+646
+37% +$3.35K ﹤0.01% 6789
2017
Q2 		$9K Buy
+1,766
New +$8.78K ﹤0.01% 6846
2017
Q1 		– Sell
-1,286
Closed -$6K – 7892
2016
Q4 		$6K Buy
+1,286
New +$6.63K ﹤0.01% 7163
2016
Q3 		– Sell
-2,627
Closed -$13K – 7876
2016
Q2 		$13K Buy
+2,627
New +$13.5K ﹤0.01% 6624
2016
Q1 		– Sell
-957
Closed -$8K – 8044
2015
Q4 		$8K Sell
957
-246
-20% -$2.83K ﹤0.01% 7434
2015
Q3 		$18K Buy
1,203
+903
+301% +$15.1K ﹤0.01% 6812
2015
Q2 		$5K Sell
300
-227
-43% -$4.28K ﹤0.01% 7879
2015
Q1 		$12K Buy
527
+85
+19% +$1.75K ﹤0.01% 7496
2014
Q4 		$10K Buy
+442
New +$6.71K ﹤0.01% 8394

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

UBS Group's PRQR Position: Q1 2026 in Review

UBS Group reduced its ProQR Therapeutics (PRQR) stake by 62% in Q1 2026, selling an estimated $807K and leaving 305,264 shares worth $495K. The position accounts for ﹤0.01% of the portfolio, ranked #6095.

UBS Group first reported a position in PRQR in Q4 2014 and has held it in 39 quarters since. The position peaked at $45M in Q4 2018. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • UBS Group held 305,264 shares of ProQR Therapeutics worth $495K as of Q1 2026.
  • UBS Group sold 492,400 ProQR Therapeutics shares in Q1 2026, an estimated $807K.
  • ProQR Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6095 holding.
  • UBS Group first reported a position in ProQR Therapeutics in Q4 2014 and has held it in 39 quarters since.
  • UBS Group's ProQR Therapeutics position peaked at $45M in Q4 2018.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.